Tomohisa Nakada Target Cytokines and IL-1β As Predictors for Anti-Inflammatory Responses in Rheumatoid Arthritis: Outcomes from an Integrated Systems Model of Relevant Cytokines
|
Chung Yin (Joey) Leung Development of a Quantitative Systems Pharmacology (QSP) model of atopic dermatitis for evaluation of novel treatments
|
Fulya Akpinar Singh Virtual Patient Generation and Selection for Non-alcoholic Steatohepatitis via Diet-induced Disease Progression Simulations
|
Fulya Akpinar Singh Identification of NASH patient characteristics associated with fibrosis response to weight loss using a quantitative systems pharmacology approach
|
Galina Kolesova Comparison Of Different Approaches To Generate Virtual Patient Populations Of Different Sizes For QSP Model Of Erythropoiesis
|
Min Liang Translational Gastrointestinal Toxicity Modeling to Support AG-636 Dose and Dose Schedule Selection in First-in-Human Study
|
Ruth Abrams A quantitative systems pharmacology (QSP) model of a trispecific T-cell engager demonstrates the importance of competition between cells in determining the dose response of T-cell engager therapies
|
Zackary Kenz CARDIOsym Quantitative Systems Pharmacology Model Prediction of Wound Healing Response Following Myocardial Infarction
|
Sergey Ermakov Suppressing TGF? activation to reduce lung fibrosis: In search for an efficacious dose regimen for alpha V integrin inhibitors.
|
Sergey Smirnov A Quantitative Systems Pharmacology Model of adverse effects of PI3Kδ inhibitors on intestine inflammation
|
Hanwen Wang Quantitative Systems Pharmacology Modeling for PD-(L)1 and CD47 Blockade in Triple-Negative Breast Cancer
|
Investigation of inflammation during Alzheimer's disease by quantitative systems pharmacology model.
|
Zinnia P Parra-Guillen A PHYSIOLOGICALLY-BASED MODEL FRAMEWORK FOR CLINICAL MODELLING OF ONCOLYTIC VIRUS
|
Oleg Demin Exploration of different descriptions of lymphocyte proliferation in QSP models of immune response
|
Oleg Demin Development of QSP model of COVID-19 based on Immune Response Template
|
Jessica Leete Incorporating inter-patient variability into preclinical to clinical translation: virtual populations for anti-PD-(L)1 treatment of NSCLC
|
Loveleena Bansal QSP Modeling of STING agonist for prediction of biomarker responses and combination therapy evaluation in NSCLC
|
Light Entrainment of the Suprachiasmatic Nucleus Circadian Clock and Implications for Personalized Alterations in Corticosterone Rhythms in Shift Work and Jet Lag
|
Hojjat Bazzazi Therapeutic implications of distinct mechanisms of oncolytic virus spread within the tumor microenvironment: investigations with a computational model
|
Stepan Lerner The QSP model of amyloid beta and tau oligomers influence on synaptic plasticity
|
Considerations for calibrating a virtual population in QSP models for auto-immune diseases
|
Federico Reali An integrated PBPK-QSP modeling framework to support the development of new drugs and regimens against tuberculosis.
|
Generation And Simulation Of Virtual Populations (VPOPs) Allows For Comparison Of Selective Estrogen Receptor Degraders (SERDs) Within Quantitative Systems Pharmacology (QSP) Model Framework
|
Aparna Mohan Development of a QSP model of Parkinson’s disease: Modeling and calibration of the α-synuclein pathway
|
Dean Bottino Development of a Semi-Mechanistic PKPD Model to Support Optimal Biological Dose Selection for TAK-573, an Immunocytokine Targeting CD38 for the Treatment of Patients with Multiple Myeloma
|
Assessing the Impact of CAR T Memory, Effector, and Exhausted Cell State Dynamics on Lymphoma Patient Trajectories through Mechanistic Modeling
|
Jared Weddell Recommendations for a Standardized Publication Protocol for a QSP Model
|
Polina Pchelintseva Quantitative systems pharmacology model for neurofilament L dynamics in Alzheimer’s disease pathology
|
Catherine Weathered Prophylactic Targeting of Bacterial Biofilms: An Agent-Based Model to Assess the Efficacy of Targeting Biofilms in Mycobacterium avium Reinfection
|
Pan-Cancer Model v2.0: A Scalable, Open-Source Implementation of a Large-Scale Mechanistic Model for Single Cell Proliferation and Death Signaling
|
Abhishek Gulati Assessment of Model Uncertainty Using a Pedigree Table
|
Kamau Pierre Clinical Quantitative Systems Pharmacology (QSP) Modeling of the Efficacy of a Novel Not-alpha IL-2 as a Mono- and Combination Immunotherapy for Advanced/Metastatic Solid Tumors
|
Satyajit Rao Developing a robust Quantitative Systems Pharmacology model of adeno-associated virus based gene therapy for clinical applications
|
Surrogate Modeling with Machine Learning for Faster VP Cohort Generation
|
Kamau Pierre Utilization of a clinical-level QSP model to critically impact dose and clinical trial design of a bispecific T cell engager
|
Mengdi Tao A Quantitative Systems Pharmacology Model Of Gaucher Disease Type 1 Provides Mechanistic Insight Into The Response To Substrate Reduction Therapy With Eliglustat
|
Tarunendu Mapder Antiviral and Antibody Treatments on SARS-Cov-2 Infected Epithelial Tissue Patch
|